Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BMS-986141 plus aspirin to prevent recurrent brain infarction after acute ischemic stroke or transient ischemic attack
2015-003959-22Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke and transient ischaemic attack (TIA) comparing BMS-986141 + aspirin with Placebo + aspirin (2 arms). Primary endpoint: Primary efficacy endpoint. Started Apr 2016; status: terminated.
02
Drugs
bms-986141
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on 2015-003959-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003959-22.